References
- Ikeda S, Chisuwa H, Kawasaki S, Ozawa J, Hoshii Y, Yokota T, Aoi T. Systemic reactive amyloidosis associated with Castleman's disease: serial changes of the concentrations of acute phase serum amyloid A and interleukin 6 in serum. J Clin Pathol 1997; 50: 965–967
- Urata K, Kawasaki S, Matsunami H, Hashikura Y, Ikegami T, Ishizone S, Momose Y, Komiyama A, Makuuchi M. Calculation of child and adult standard liver volume for liver transplantation. Hepatology 1995; 21: 1317–1321
- Leger-Ravet M B, Peuchmaur M, Devergne O, Audouin J, Raphael M, Van Damme J, Galanaud P, Diebold J, Emilie D. Interleukin-6 gene expression in Castleman's disease. Blood 1991; 78: 2923–2930
- Hagihara K, Nishikawa T, Isobe T, Song J, Sugamata Y, Yoshizaki K. IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system. Biochem Biophys Res Commun 2004; 314: 363–369
- Lachmann H J, Gilbertson J A, Gillmore J D, Hawkins P N, Pepys M B. Unicentric Castleman's disease complicated by systemic AA amyloidosis: a curable disease. Q J Med 2002; 95: 211–218
- Perfetti V, Bellotti V, Maggi A, Arbustini E, De Benedetti F, Paulli M, Marinone M G, Merlini G. Reversal of nephrotic syndrome due to reactive amyloidosis (AA-type) after excision of localized Castleman's disease. Am J Hematol 1994; 46: 189–193
- Paydas S, Gonlusen G, Sagliker Y. Regression of nephrotic syndrome with colchicine therapy secondary to amyloidosis with associated Castleman's disease. Nephron 1995; 71: 463–464
- Ishihara T, Uchino F. Pathological study on amyloidosis. Amyloid dormation and resorption in Kpuffer cell. Recent Adv In RES Res 1975; 15: 145–171
- Takahashi M, Yokota T, Kawano H, Gondo T, Ishihara T, Uchino F. Ultrastructural evidence for intracellular formation of amyloid fibrils in macrophages. Virchows Arch A Pathol Anat Histopathol 1989; 415: 411–419